120 related articles for article (PubMed ID: 1410576)
1. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy.
Slevin NJ; Hendry JH; Roberts SA; Agren-Cronqvist A
Radiother Oncol; 1992 Aug; 24(4):215-20. PubMed ID: 1410576
[TBL] [Abstract][Full Text] [Related]
2. Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets.
Roberts SA; Hendry JH; Slevin NJ
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1173-82. PubMed ID: 9392560
[TBL] [Abstract][Full Text] [Related]
3. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
Terhaard CH; Kal HB; Hordijk GJ
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
[TBL] [Abstract][Full Text] [Related]
4. Time factors in larynx tumor radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers.
Roberts SA; Hendry JH
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1247-57. PubMed ID: 10613320
[TBL] [Abstract][Full Text] [Related]
5. Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centres in Manchester, UK and Toronto, Canada.
Hendry JH; Roberts SA; Slevin NJ; Keane TJ; Barton MB; Agren-Cronqvist A
Radiother Oncol; 1994 Apr; 31(1):14-22. PubMed ID: 8041895
[TBL] [Abstract][Full Text] [Related]
6. Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters.
Ricciardelli EJ; Weymuller EA; Koh WJ; Austin-Seymour M; DeSautel MG; Laramore GE
Arch Otolaryngol Head Neck Surg; 1994 Jul; 120(7):737-42. PubMed ID: 8018326
[TBL] [Abstract][Full Text] [Related]
7. The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx.
Robertson AG; Robertson C; Boyle P; Symonds RP; Wheldon TE
Eur J Cancer; 1993; 29A(4):501-10. PubMed ID: 8435200
[TBL] [Abstract][Full Text] [Related]
8. Local control of T3 carcinomas after accelerated fractionation: a look at the "gap".
Wang CC; Efird J; Nakfoor B; Martins P
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):439-41. PubMed ID: 8655365
[TBL] [Abstract][Full Text] [Related]
9. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer.
Maciejewski B; Majewski S
Radiother Oncol; 1991 Jul; 21(3):163-70. PubMed ID: 1924851
[TBL] [Abstract][Full Text] [Related]
10. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients.
Suwinski R; Sowa A; Rutkowski T; Wydmanski J; Tarnawski R; Maciejewski B
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):399-412. PubMed ID: 12738315
[TBL] [Abstract][Full Text] [Related]
11. Tumour volume: implications in T2/T3 glottic/supraglottic squamous cell carcinoma.
Lo SM; Venkatesan V; Matthews TW; Rogers J
J Otolaryngol; 1998 Oct; 27(5):247-51. PubMed ID: 9800621
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of human squamous cell carcinoma of the larynx to fractionated radiotherapy.
Rezvani M; Fowler JF; Hopewell JW; Alcock CJ
Br J Radiol; 1993 Mar; 66(783):245-55. PubMed ID: 8472118
[TBL] [Abstract][Full Text] [Related]
13. Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis.
Robertson AG; Robertson C; Perone C; Clarke K; Dewar J; Elia MH; Hurman D; MacDougall RH; Yosef HM
Radiother Oncol; 1998 Aug; 48(2):165-73. PubMed ID: 9783888
[TBL] [Abstract][Full Text] [Related]
14. The impact of treatment time and smoking on local control and complications in T1 glottic cancer.
van der Voet JC; Keus RB; Hart AA; Hilgers FJ; Bartelink H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):247-55. PubMed ID: 9788401
[TBL] [Abstract][Full Text] [Related]
15. [Radiotherapy of carcinoma of the larynx--dose and function preservation].
Nakano M; Iida K; Sato S; Sakata S; Sueyama H
Gan No Rinsho; 1985 Sep; 31(12):1602-4. PubMed ID: 4079049
[TBL] [Abstract][Full Text] [Related]
16. Overall time in telecobalt therapy for T1 glottic carcinoma treated with 2 Gy per day.
Inoue T; Inoue T; Teshima T; Murayama S; Yamazaki H; Nose T; Tanaka E
Strahlenther Onkol; 1995 Aug; 171(8):475-7. PubMed ID: 7652672
[TBL] [Abstract][Full Text] [Related]
17. 331 cases of clinically node-negative supraglottic carcinoma of the larynx: a study of a modest size fixed field radiotherapy approach.
Sykes AJ; Slevin NJ; Gupta NK; Brewster AE
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1109-15. PubMed ID: 10725620
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy alone or combined with neck dissection for T1-T2 carcinoma of the pyriform sinus: an alternative to conservation surgery.
Mendenhall WM; Parsons JT; Stringer SP; Cassisi NJ; Million RR
Int J Radiat Oncol Biol Phys; 1993 Dec; 27(5):1017-27. PubMed ID: 8262822
[TBL] [Abstract][Full Text] [Related]
19. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions.
Withers HR; Peters LJ; Taylor JM; Owen JB; Morrison WH; Schultheiss TE; Keane T; O'Sullivan B; van Dyk J; Gupta N
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):549-62. PubMed ID: 7558943
[TBL] [Abstract][Full Text] [Related]
20. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation.
Maciejewski B; Withers HR; Taylor JM; Hliniak A
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):831-43. PubMed ID: 2921175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
